APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027

In Situ ハイブリダイゼーション(ISH)のアジア太平洋市場予測(~2027):消耗品、装置、ソフトウェア

◆タイトル:APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027
◆商品コード:BT8237-23
◆調査・発行会社:MarketsandMarkets
◆発行日:2023年1月10日
◆ページ数:154
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア太平洋
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥0見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥0見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥0見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社発行の当調査資料では、アジア太平洋のIn Situ ハイブリダイゼーション(ISH)市場規模が、2022年363百万ドルから2027年744百万ドルまで年平均15.4%拡大すると予測しています。当書は、In Situ ハイブリダイゼーション(ISH)のアジア太平洋市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(消耗品、装置、ソフトウェア)分析、技術別(DNA FISH、RNA FISH、PNA FISH、CISH)分析、用途別(癌、免疫、神経科学、細胞診)分析、エンドユーザー別(病院、製薬、バイオテクノロジー、CRO)分析、国別分析、競争状況などの内容をまとめております。なお、参入企業情報として、Abbott (US)、Abbott Laboratories (US)、Thermo Fisher Scientific (US)、Danaher Corporation (US)、Merck (Germany)、F. Hoffmann-La Roche (Switzerland)、BioView (Israel)、Agilent Technologies (US)、Biocare Medical (US)、Bio-Techne Corporation (US)などが含まれています。

“The Asia Pacific in situ hybridization market is projected to reach USD 744 million by 2027 from USD 363 million in 2022, at a CAGR of 15.4% during the forecast period.” Companion diagnostic products showcase a significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a substantial role in developing companion diagnostics because of their ability to evaluate morphology and gene amplification simultaneously. This has increased the adoption of ISH-based consumables across companion diagnostic tests.

“The kits & reagents segment accounted for the highest share in the Asia Pacific ISH consumables market revenue for the year 2021”
The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.

“Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021”
Based on the end users the Asia Pacific in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.

“China: The fastest-growing country in the Asia Pacific in situ hybridization market”
The Asia Pacific in situ hybridization market is segmented into Japan, China, India, South Korea, Taiwan, Singapore, Australia, New Zealand, and Rest of Asia Pacific. China market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the country, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the country.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: C-level – 25%, D-level – 20%, and Others – 55%

Lists of Companies Profiled in the Report:
• Abbott (US)
• Abbott Laboratories (US)
• Thermo Fisher Scientific (US)
• Danaher Corporation (US)
• Merck (Germany)
• F. Hoffmann-La Roche (Switzerland)
• BioView (Israel)
• Agilent Technologies (US)
• Biocare Medical (US)
• Bio-Techne Corporation (US)
• QIAGEN (Germany)
• PerkinElmer (US)
• Enzo Biochem (US)
• Bio-Rad Laboratories (US)
• Abnova Corporation (Taiwan)
• BioGenex Laboratories (US)
• OpGen (US)
• Bio SB (US)
• Abcam (UK)
• Zytomed (Germany)
• 10x Genomics Inc. (US)
• NeoGenomics Laboratories (US).

Research Coverage:
This report provides a detailed picture of the Asia Pacific in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and country. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Asia Pacific in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS & EXCLUSIONS 22
1.3 MARKET SCOPE 23
1.3.1 MARKETS COVERED 23
1.4 YEARS CONSIDERED 23
1.5 CURRENCY CONSIDERED 24
1.6 LIMITATIONS 24
1.7 STAKEHOLDERS 24
1.8 SUMMARY OF CHANGES 24
2 RESEARCH METHODOLOGY 25
2.1 RESEARCH DATA 25
FIGURE 1 RESEARCH DESIGN 25
2.1.1 SECONDARY DATA 25
2.1.2 PRIMARY DATA 26
FIGURE 2 BREAKDOWN OF PRIMARIES: APAC IN SITU HYBRIDIZATION MARKET 26
2.2 MARKET ESTIMATION METHODOLOGY 27
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION) 27
FIGURE 4 APAC IN SITU HYBRIDIZATION MARKET SIZE, 2021 (USD MILLION) 27
FIGURE 5 APAC IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022−2027) 28
FIGURE 6 APAC IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES 28
2.3 MARKET DATA ESTIMATION & TRIANGULATION 29
FIGURE 7 DATA TRIANGULATION METHODOLOGY 29
2.4 INDUSTRY INSIGHTS 30
2.5 RESEARCH ASSUMPTIONS 30
3 EXECUTIVE SUMMARY 31
FIGURE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 31
FIGURE 9 APAC IN SITU HYBRIDIZATION MARKET SHARE, BY PRODUCT, 2021 31
FIGURE 10 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 32
FIGURE 11 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021 32
FIGURE 12 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 APAC IN SITU HYBRIDIZATION MARKET OVERVIEW 34
FIGURE 13 GROWING FOCUS ON COMPANION DIAGNOSTICS AND INCREASING CANCER INCIDENCE TO FAVOR MARKET GROWTH 34
4.2 APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2021 VS. 2027 (USD MILLION) 35
FIGURE 14 HOSPITAL & DIAGNOSTIC LABORATORIES TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 36
5.2 MARKET DYNAMICS 36
FIGURE 15 APAC IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 36
TABLE 1 APAC IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS 37
5.2.1 DRIVERS 37
5.2.1.1 Increasing incidence of genetic disorders and cancer 37
TABLE 2 NEW CASES OF CANCER IN ASIA, 2020 VS. 2025 37
FIGURE 16 HEMOPHILIA OCCURRENCE, BY REGION 38
5.2.1.2 Growing awareness about companion diagnostics 38
5.2.2 OPPORTUNITIES 38
5.2.2.1 Untapped markets in developing countries 38
5.2.3 CHALLENGES 39
5.2.3.1 Shortage of skilled professionals 39
5.3 PORTER’S FIVE FORCES ANALYSIS 39
TABLE 3 APAC IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS 39
5.3.1 THREAT FROM NEW ENTRANTS 39
5.3.2 THREAT FROM SUBSTITUTES 39
5.3.3 BARGAINING POWER OF BUYERS 40
5.3.4 BARGAINING POWER OF SUPPLIERS 40
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 40
5.4 SUPPLY CHAIN ANALYSIS 40
FIGURE 17 SUPPLY CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET 41
5.5 VALUE CHAIN ANALYSIS 42
FIGURE 18 VALUE CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET 42
5.6 ECOSYSTEM ANALYSIS 43
FIGURE 19 ECOSYSTEM ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET 43
5.7 KEY CONFERENCES & EVENTS IN 2022–2023 43
TABLE 4 KEY CONFERENCES & EVENTS, 2022–2023 43
5.8 REGULATORY ANALYSIS 44
5.8.1 FDA APPROVALS 44
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 44
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 44
5.9 PRICING ANALYSIS 45
TABLE 6 PRICING ANALYSIS OF IN SITU HYBRIDIZATION PRODUCTS 45
5.9.1 APAC IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TRENDS 45
TABLE 7 PRICING ANALYSIS OF FISH TESTS IN INDIA (2021) 46
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 47
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 47
FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC 47
5.10.2 BUYING CRITERIA FOR IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC 48
FIGURE 21 KEY BUYING CRITERIA FOR END USERS 48
6 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT 49
6.1 INTRODUCTION 50
TABLE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 50
6.2 CONSUMABLES 50
TABLE 9 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 50
TABLE 10 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION) 51
6.2.1 PROBES 51
6.2.1.1 Growing preference for direct localization of DNA/RNA sequences using probes to drive market 51
TABLE 11 APAC IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION) 51
6.2.2 KITS & REAGENTS 52
6.2.2.1 Growing focus on companion diagnostics to boost demand 52
TABLE 12 APAC IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 52
6.2.3 ACCESSORIES 52
6.2.3.1 Use of accessories for optimal performance of FISH and CISH probes to propel adoption 52
TABLE 13 APAC IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION) 53
6.3 INSTRUMENTS 53
6.3.1 RISING NEED FOR AUTOMATED SYSTEMS TO SUPPORT MARKET 53
TABLE 14 APAC IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 54
6.4 SOFTWARE 54
6.4.1 GROWING DEMAND FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET 54
TABLE 15 APAC IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION) 55
7 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION 56
7.1 INTRODUCTION 57
TABLE 16 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 57
7.2 CANCER DIAGNOSTICS 57
7.2.1 GROWING IMPORTANCE OF COMPANION DIAGNOSTICS TO DRIVE MARKET 57
TABLE 17 APAC IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 58
7.3 CYTOLOGY 58
7.3.1 GROWING DEMAND FOR FISH FOR DETECTION OF CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET 58
TABLE 18 APAC IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 59
7.4 INFECTIOUS DISEASE DIAGNOSTICS 59
7.4.1 NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN INFECTIOUS DISEASE DIAGNOSIS TO AID GROWTH 59
TABLE 19 APAC IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION) 60
7.5 NEUROSCIENCE 60
7.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO BOOST R&D ACTIVITIES 60
TABLE 20 APAC IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION) 61
7.6 IMMUNOLOGY 61
7.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE GROWTH 61
TABLE 21 APAC IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 62
8 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY 63
8.1 INTRODUCTION 64
TABLE 22 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 64
8.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 64
TABLE 23 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 64
TABLE 24 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
8.2.1 DNA FLUORESCENCE IN SITU HYBRIDIZATION 65
8.2.1.1 Need to ensure stability of genetic material to drive market 65
TABLE 25 APAC DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 66
8.2.2 RNA FLUORESCENCE IN SITU HYBRIDIZATION 66
8.2.2.1 Increasing biomedical research to support market growth 66
TABLE 26 APAC RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 67
8.2.3 PNA FLUORESCENCE IN SITU HYBRIDIZATION 67
8.2.3.1 Increased applications in infectious disease diagnosis to boost market 67
TABLE 27 APAC PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 68
8.3 CHROMOGENIC IN SITU HYBRIDIZATION (CISH) 68
8.3.1 COST-EFFECTIVENESS OF CISH OVER FISH TO BOOST MARKET GROWTH 68
TABLE 28 APAC CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 69
9 APAC IN SITU HYBRIDIZATION MARKET, BY END USER 70
9.1 INTRODUCTION 71
TABLE 29 APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 71
9.2 HOSPITAL & DIAGNOSTIC LABORATORIES 71
9.2.1 GROWING VOLUME OF MOLECULAR TESTS TO DRIVE MARKET 71
TABLE 30 APAC IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 72
9.3 ACADEMIC & RESEARCH INSTITUTES 72
9.3.1 GROWING RESEARCH ON CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET 72
TABLE 31 APAC IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 73
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 73
9.4.1 NEED TO DEVELOP PRECISION TREATMENTS TO DRIVE DEMAND FOR ISH 73
TABLE 32 APAC IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 74
9.5 CONTRACT RESEARCH ORGANIZATIONS 74
9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO BOOST MARKET 74
TABLE 33 APAC IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 75
10 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY 76
10.1 INTRODUCTION 77
FIGURE 22 APAC IN SITU HYBRIDIZATION MARKET SNAPSHOT 77
TABLE 34 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
10.1.1 JAPAN 78
10.1.1.1 Growing focus on personalized diagnostics to support market growth 78
TABLE 35 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 79
TABLE 36 JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 79
TABLE 37 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 79
TABLE 38 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 80
TABLE 39 JAPAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 80
TABLE 40 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 80
10.1.2 CHINA 81
10.1.2.1 China to register highest CAGR during forecast period 81
TABLE 41 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 81
TABLE 42 CHINA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 43 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 82
TABLE 44 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 82
TABLE 45 CHINA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 82
TABLE 46 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 83
10.1.3 INDIA 83
10.1.3.1 Collaborations between hospitals and diagnostic labs to propel market growth in India 83
TABLE 47 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 83
TABLE 48 INDIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 49 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 84
TABLE 50 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 84
TABLE 51 INDIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 85
TABLE 52 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85
10.1.4 SOUTH KOREA 85
10.1.4.1 Robust healthcare infrastructure to boost growth 85
TABLE 53 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 86
TABLE 54 SOUTH KOREA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 55 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 86
TABLE 56 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 87
TABLE 57 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 58 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 87
10.1.5 TAIWAN 88
10.1.5.1 Improving cancer research and care to propel demand for ISH 88
TABLE 59 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 88
TABLE 60 TAIWAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 61 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 89
TABLE 62 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 89
TABLE 63 TAIWAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 64 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 90
10.1.6 SINGAPORE 90
10.1.6.1 Government initiatives to make cancer treatment more affordable to contribute to growth 90
TABLE 65 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 90
TABLE 66 SINGAPORE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 91
TABLE 67 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 91
TABLE 68 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 91
TABLE 69 SINGAPORE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 70 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 92
10.1.7 AUSTRALIA 93
10.1.7.1 Increasing public-private investments in cancer research to boost demand 93
TABLE 71 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 93
TABLE 72 AUSTRALIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 94
TABLE 73 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 94
TABLE 74 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 94
TABLE 75 AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 95
TABLE 76 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95
10.1.8 NEW ZEALAND 95
10.1.8.1 Rising cases of cancer to propel growth 95
TABLE 77 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 96
TABLE 78 NEW ZEALAND: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 96
TABLE 79 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 96
TABLE 80 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 97
TABLE 81 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 97
TABLE 82 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 97
10.1.9 REST OF ASIA PACIFIC 98
TABLE 83 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 98
TABLE 84 REST OF ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 98
TABLE 85 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION) 99
TABLE 86 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 99
TABLE 87 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION) 99
TABLE 88 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 100
11 COMPETITIVE LANDSCAPE 101
11.1 INTRODUCTION 101
11.2 RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS 101
TABLE 89 APAC IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 101
11.3 MARKET SHARE ANALYSIS 102
FIGURE 23 APAC IN SITU HYBRIDIZATION MARKET SHARE ANALYSIS (2021) 102
11.4 REVENUE SHARE ANALYSIS 103
FIGURE 24 REVENUE ANALYSIS OF KEY COMPANIES (2019−2021) 103
11.5 COMPANY EVALUATION QUADRANT 104
11.5.1 STARS 104
11.5.2 EMERGING LEADERS 104
11.5.3 PERVASIVE PLAYERS 104
11.5.4 PARTICIPANTS 104
FIGURE 25 APAC IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021) 105
11.6 COMPETITIVE SCENARIO AND TRENDS 106
11.6.1 PRODUCT LAUNCHES 106
TABLE 90 APAC IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES, 2019–2022 106
11.6.2 DEALS 107
TABLE 91 APAC IN SITU HYBRIDIZATION MARKET: DEALS, 2019–2022 107

12 COMPANY PROFILES 108
12.1 KEY COMPANIES 108
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT LABORATORIES 108
TABLE 92 ABBOTT LABORATORIES: BUSINESS OVERVIEW 108
FIGURE 26 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 109
12.1.2 F. HOFFMANN-LA ROCHE AG 111
TABLE 93 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 111
FIGURE 27 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 112
12.1.3 THERMO FISHER SCIENTIFIC, INC. 114
TABLE 94 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 114
FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 115
12.1.4 DANAHER CORPORATION 117
TABLE 95 DANAHER CORPORATION: BUSINESS OVERVIEW 117
FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 118
12.1.5 AGILENT TECHNOLOGIES, INC. 120
TABLE 96 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 120
FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021) 121
12.1.6 BIOCARE MEDICAL 123
TABLE 97 BIOCARE MEDICAL: BUSINESS OVERVIEW 123
12.1.7 BIO-TECHNE CORPORATION 125
TABLE 98 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 125
FIGURE 31 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021) 126
12.1.8 QIAGEN N.V. 128
TABLE 99 QIAGEN N.V.: BUSINESS OVERVIEW 128
FIGURE 32 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 129
12.1.9 MERCK KGAA 130
TABLE 100 MERCK KGAA: BUSINESS OVERVIEW 130
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021) 131
12.1.10 PERKINELMER 132
TABLE 101 PERKINELMER: BUSINESS OVERVIEW 132
FIGURE 34 PERKINELMER: COMPANY SNAPSHOT (2021) 133
12.1.11 ENZO BIOCHEM 134
TABLE 102 ENZO BIOCHEM: BUSINESS OVERVIEW 134
FIGURE 35 ENZO BIOCHEM: COMPANY SNAPSHOT (2021) 135
12.1.12 BIO-RAD LABORATORIES 137
TABLE 103 BIO-RAD LABORATORIES: BUSINESS OVERVIEW 137
FIGURE 36 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021) 138
12.1.13 ABNOVA CORPORATION 139
TABLE 104 ABNOVA CORPORATION: BUSINESS OVERVIEW 139
12.1.14 BIOGENEX LABORATORIES 140
TABLE 105 BIOGENEX LABORATORIES: BUSINESS OVERVIEW 140
12.1.15 OPGEN INC. 142
TABLE 106 OPGEN INC.: BUSINESS OVERVIEW 142
FIGURE 37 OPGEN INC.: COMPANY SNAPSHOT (2021) 143
12.1.16 BIO SB 144
TABLE 107 BIO SB: BUSINESS OVERVIEW 144
12.1.17 ABCAM 145
TABLE 108 ABCAM: BUSINESS OVERVIEW 145
FIGURE 38 ABCAM: COMPANY SNAPSHOT (2021) 145
12.1.18 ZYTOMED SYSTEMS GMBH 147
TABLE 109 ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW 147
12.1.19 NEOGENOMICS LABORATORIES 148
TABLE 110 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW 148
FIGURE 39 NEOGENOMICS LABORATORIES: COMPANY SNAPSHOT (2021) 148
12.1.20 BIOVIEW 150
TABLE 111 BIOVIEW: BUSINESS OVERVIEW 150
FIGURE 40 BIOVIEW: COMPANY SNAPSHOT (2021) 150
12.1.21 10X GENOMICS 151
TABLE 112 10X GENOMICS: BUSINESS OVERVIEW 151
FIGURE 41 10X GENOMICS: COMPANY SNAPSHOT (2021) 151
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX 153
13.1 DISCUSSION GUIDE 153
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 155
13.3 CUSTOMIZATION OPTIONS 157
13.4 RELATED REPORTS 157
13.5 AUTHOR DETAILS 158



★調査レポート[In Situ ハイブリダイゼーション(ISH)のアジア太平洋市場予測(~2027):消耗品、装置、ソフトウェア] ( APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027 / BT8237-23) 販売に関する免責事項
[In Situ ハイブリダイゼーション(ISH)のアジア太平洋市場予測(~2027):消耗品、装置、ソフトウェア] ( APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027 / BT8237-23) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆